Vertex Pharmaceuticals Incorporated

VRTX

US92532F1003

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 08/06/2024 am IST			5-day change	1st Jan Change
483 ^USD	-0.51%		+6.08%	+18.72%

07/06	Vertex Pharmaceuticals Says Phase 3 Data Show Trikafta Improves Lung Function in Cystic Fibrosis Patients	MT
05/06	Vertex Pharmaceuticals Insider Sold Shares Worth $1,495,000, According to a Recent SEC Filing	MT

Presenter SpeechMichael Partridge (Executives)Good evening. Welcome to the Vertex Third Quarte...

This article is reserved for subscribers

Signed up already?

Not subscribed yet?

Latest news about Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Says Phase 3 Data Show Trikafta Improves Lung Function in Cystic Fibrosis Patients	07/06	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,495,000, According to a Recent SEC Filing	06/06	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,000,500, According to a Recent SEC Filing	06/06	MT
Transcript : Vertex Pharmaceuticals Incorporated Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 04:00 PM	05/06
Vertex Pharmaceuticals Insider Sold Shares Worth $2,033,159, According to a Recent SEC Filing	04/06	MT
BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $500 From $480	31/05	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,478,068, According to a Recent SEC Filing	31/05	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $715,205, According to a Recent SEC Filing	30/05	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,168,704, According to a Recent SEC Filing	25/05	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $6,795,294, According to a Recent SEC Filing	23/05	MT
ADDvise Group’s Axelerist Bags $1.4 Million Order for Medical, Lab Equipment	21/05	MT
Vertex Pharmaceuticals Incorporated completed the acquisition of Alpine Immune Sciences, Inc. from a group of shareholders.	20/05	CI
Declaration of Voting Results by Vertex Pharmaceuticals Incorporated	16/05	CI
Declaration of Voting Results by Vertex Pharmaceuticals Incorporated	16/05	CI
Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director	15/05	CI
Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $520 From $497	14/05	MT
Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone	11/05	MT
FOMO is Back	07/05
ANALYST RECOMMENDATIONS : Nvidia, The Home Depot, Lowe's, Rollins...	07/05
Leerink Partners Adjusts Vertex Pharmaceuticals' Price Target to $529 From $511	07/05	MT
Stifel Adjusts Vertex Pharmaceuticals' Price Target to $420 From $430	07/05	MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $456 From $450, Keeps Overweight Rating	07/05	MT
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $402 From $413, Keeps Equalweight Rating	07/05	MT
RBC Adjusts Price Target on Vertex Pharmaceuticals to $424 From $417, Keeps Sector Perform Rating	07/05	MT
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $577 From $574, Keeps Buy Rating	07/05	MT

Chart Vertex Pharmaceuticals Incorporated

Duration

Period

Chart Vertex Pharmaceuticals Incorporated

More charts

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

Biotechnology & Medical Research

Calendar

11/06/2024 - Goldman Sachs Global Healthcare Conference

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Vertex Pharmaceuticals Incorporated : Vertex and Crispr to market $2.2 million treatment for sickle cell disease

December 11, 2023 at 04:17 pm IST

More Strategies

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

483 USD

Average target price

463.5 USD

Spread / Average Target

-4.04%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
BIONTECH SE	-4.93%	24.21B
ARGENX SE	+3.23%	22.78B
GENMAB A/S	-10.44%	17.96B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-13.31%	16.37B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.58B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.66B
INSMED INCORPORATED	+83.45%	9.17B

Bio Therapeutic Drugs

Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Latest news about Vertex Pharmaceuticals Incorporated

Chart Vertex Pharmaceuticals Incorporated

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Vertex Pharmaceuticals Incorporated

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs